Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer

Monica Rampino, A. Bacigalupo, E. Russi, M. Schena, L. Lastrucci, C. Iotti, A. Reali, A. Musu, V. Balcet, C. Piva, S. Bustreo, F. Munoz, R. Ragona, R. Corvò, U. Ricardi

Research output: Contribution to journalArticle

Abstract

Background: To determine the potential activity and tolerability of sequential treatment in head and neck cancer, we conducted a phase II trial based on induction chemotherapy of two cycles of taxotere, cisplatin and 5-fluorouracil followed by radiotherapy plus weekly cetuximab. Patients and Methods: Thirty-six patients with stage III or IV squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx were treated and evaluated for response and acute toxicity. Results: Eighty-one percent of patients had stage IV disease and 42% had hypopharyngeal and oral cavity primaries. The overall response rate was 81.8%, with 60.6% complete response and 33.3% partial response. Severe toxicities were febrile neutropenia (6%) during induction chemotherapy and dermatitis (48%), mucositis (33%) and dysphagia (12%) during the concurrent phase. Conclusion: Our protocol proved to be feasible, effective and well tolerated. This sequential strategy should be further investigated.

Original languageEnglish
Pages (from-to)195-199
Number of pages5
JournalAnticancer Research
Volume32
Issue number1
Publication statusPublished - Jan 2012

Keywords

  • Cetuximab
  • Head and neck cancer
  • Induction chemotherapy
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer'. Together they form a unique fingerprint.

  • Cite this

    Rampino, M., Bacigalupo, A., Russi, E., Schena, M., Lastrucci, L., Iotti, C., Reali, A., Musu, A., Balcet, V., Piva, C., Bustreo, S., Munoz, F., Ragona, R., Corvò, R., & Ricardi, U. (2012). Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer. Anticancer Research, 32(1), 195-199.